Agtc

Description

• AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy productsFind AGTC on YouTube at goo.gl/sMdJqX.
• 

  Headquarters:14193 Northwest 119Th Terrace Suite #10, Alachua, Florida, United States

  More
• 

  Phone Number: +1 386-462-2204

• 

  Website: https://www.agtc.com

• 

  Employees:94

• 

  Revenue:$100 - 250M

• 

  Legal Name:Agtc

• Agtc's Social Media

  
• Is this data correct?

• |  NAICS Code: 541715  |

  Show More